Makoto Natsumeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Makoto Natsumeda has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Aisha Khan
Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
2 shared publicationsAngela C Rieger
Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
2 shared publications- Ivonne Hernandez Schulman
Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
2 shared publications Krystalenia Valasaki
Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
2 shared publicationsMonisha N Banerjee
Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
2 shared publicationsVictoria Florea
Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
2 shared publications
Latest Publications
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (13) , e038770
Angiography‐Based Blood Flow Quantification After Revascularization in Acute Coronary Syndromes
Background: In patients presenting with acute coronary syndromes (ACS), impaired coronary blood flow (CBF) after percutaneous coronary interventions (PCI) is linked to mortality. We developed a novel angiography‐based approach for blood flow quantification using automatic contrast bolus tracking. Therefore, this study aimed to investigate the clinical impact of angiography‐based blood flow quantification on major adverse cardiovascular events (MACE) after PCI in patients with ACS. Methods: Prospective, multicenter, nested case–control study of patients presenting ACS. A propensity score was used to match patients with and without MACE at 1 year of follow‐up. MACE was defined as cardiovascular death, myocardial infarction, hospitalization for heart failure, or ischemia‐driven revascularization. CBF was measured automatically from angiograms after PCI. Results: One hundred sixty‐two patients were included. The mean age was 68.3±13.0 years, 83% were male, and 33% had diabetes. Overall, 66% of patients presented with ST‐segment–elevation myocardial infarction. CBF after PCI was lower after ST‐segment–elevation myocardial infarction compared with other clinical presentations (74.1±47.0 mL/min ST‐segment–elevation myocardial infarction, 89.1±45.8 mL/min, non‐ST‐segment–elevation myocardial infarction, 95.7±48.8 mL/min, unstable angina, P =0.046). Patients with low post‐PCI CBF (P =0.001). Conclusions: After PCI, automatic quantification of CBF using angiography was associated with MACE in patients with ACS. Risk stratification using post‐PCI CBF‐derived angiography may enable tailored management strategies for individuals with ACS.
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (13) , e038770
Open AccessAngiography‐Based Blood Flow Quantification After Revascularization in Acute Coronary Syndromes
Background: In patients presenting with acute coronary syndromes (ACS), impaired coronary blood flow (CBF) after percutaneous coronary interventions (PCI) is linked to mortality. We developed a novel angiography‐based approach for blood flow quantification using automatic contrast bolus tracking. Therefore, this study aimed to investigate the clinical impact of angiography‐based blood flow quantification on major adverse cardiovascular events (MACE) after PCI in patients with ACS. Methods: Prospective, multicenter, nested case–control study of patients presenting ACS. A propensity score was used to match patients with and without MACE at 1 year of follow‐up. MACE was defined as cardiovascular death, myocardial infarction, hospitalization for heart failure, or ischemia‐driven revascularization. CBF was measured automatically from angiograms after PCI. Results: One hundred sixty‐two patients were included. The mean age was 68.3±13.0 years, 83% were male, and 33% had diabetes. Overall, 66% of patients presented with ST‐segment–elevation myocardial infarction. CBF after PCI was lower after ST‐segment–elevation myocardial infarction compared with other clinical presentations (74.1±47.0 mL/min ST‐segment–elevation myocardial infarction, 89.1±45.8 mL/min, non‐ST‐segment–elevation myocardial infarction, 95.7±48.8 mL/min, unstable angina, P =0.046). Patients with low post‐PCI CBF (P =0.001). Conclusions: After PCI, automatic quantification of CBF using angiography was associated with MACE in patients with ACS. Risk stratification using post‐PCI CBF‐derived angiography may enable tailored management strategies for individuals with ACS.
- Open Access
- 1 August 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 7 (8) , ytad378
Short-term recurrence of takotsubo syndrome with phenotypic variation: a case report
Background: Takotsubo syndrome (TTS) is an acute and usually reversible heart failure syndrome characterized as an uncommon left ventricular (LV) cardiomyopathy. Recurrence of TTS is rare, estimated to be 1–6%. We report a rare case of TTS that occurred three times in 2 months but manifested various phenotypes. Case summary: A 68-year-old woman was admitted to our hospital with acute-onset chest pain and hypertension. The coronary angiography findings were normal, although left ventriculography revealed inferior wall hypokinesis, leading to a mid-ventricular TTS diagnosis. She was discharged on Day 3 after her symptoms improved and vitals stabilized. The patient’s condition remained uneventful until 2-week post-discharge, when acute chest pain and hypertension recurred. She was admitted again with the same diagnosis. However, LV morphology revealed an apical ballooning pattern, with inferior LV wall hypokinesis. She was discharged on Day 7 after her symptoms and electrocardiography findings improved but was readmitted again 2 weeks later after acute chest pain and hypertension recurred. Left ventriculography performed a third time demonstrated mid-ventricular TTS. The patient was prescribed additional medications and discharged on Day 12. Her electrocardiography findings normalized, and the patient remained asymptomatic without recurrence 4 months after the initial presentation. Discussion: Recurrence and phenotypic change of TTS are rare. Some cases have been reported but occurring months to years after initial diagnosis. Combined treatment with β-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists may be more effective to prevent the recurrence than monotherapies.
- 1 August 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 7 (8) , ytad378
Open AccessShort-term recurrence of takotsubo syndrome with phenotypic variation: a case report
Background: Takotsubo syndrome (TTS) is an acute and usually reversible heart failure syndrome characterized as an uncommon left ventricular (LV) cardiomyopathy. Recurrence of TTS is rare, estimated to be 1–6%. We report a rare case of TTS that occurred three times in 2 months but manifested various phenotypes. Case summary: A 68-year-old woman was admitted to our hospital with acute-onset chest pain and hypertension. The coronary angiography findings were normal, although left ventriculography revealed inferior wall hypokinesis, leading to a mid-ventricular TTS diagnosis. She was discharged on Day 3 after her symptoms improved and vitals stabilized. The patient’s condition remained uneventful until 2-week post-discharge, when acute chest pain and hypertension recurred. She was admitted again with the same diagnosis. However, LV morphology revealed an apical ballooning pattern, with inferior LV wall hypokinesis. She was discharged on Day 7 after her symptoms and electrocardiography findings improved but was readmitted again 2 weeks later after acute chest pain and hypertension recurred. Left ventriculography performed a third time demonstrated mid-ventricular TTS. The patient was prescribed additional medications and discharged on Day 12. Her electrocardiography findings normalized, and the patient remained asymptomatic without recurrence 4 months after the initial presentation. Discussion: Recurrence and phenotypic change of TTS are rare. Some cases have been reported but occurring months to years after initial diagnosis. Combined treatment with β-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists may be more effective to prevent the recurrence than monotherapies.
- Open Access
- 19 February 2022
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 11 (1) , 59-72
Allogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction
Left ventricular hypertrophy and heart failure with preserved ejection fraction (HFpEF) are primary manifestations of the cardiorenal syndrome in patients with chronic kidney disease (CKD). Therapies that improve morbidity and mortality in HFpEF are lacking. Cell-based therapies promote cardiac repair in ischemic and non-ischemic cardiomyopathies. We hypothesized that cell-based therapy ameliorates CKD-induced HFpEF. Yorkshire pigs (n = 26) underwent 5/6 embolization-mediated nephrectomy. CKD was confirmed by increased creatinine and decreased glomerular filtration rate (GFR). Mean arterial pressure (MAP) was not different between groups from baseline to 4 weeks. HFpEF was evident at 4 weeks by increased LV mass, relative wall thickening, end-diastolic pressure, and end-diastolic pressure-volume relationship, with no change in ejection fraction (EF). Four weeks post-embolization, allogeneic (allo) bone marrow-derived mesenchymal stem cells (MSC; 1 × 107 cells), allo-kidney-derived stem cells (KSC; 1 × 107 cells), allo-cell combination therapy (ACCT; MSC + KSC; 1:1 ratio; total = 1 × 107 cells), or placebo (Plasma-Lyte) was delivered via intra-renal artery. Eight weeks post-treatment, there was a significant increase in MAP in the placebo group (21.89 ± 6.05 mmHg) compared to the ACCT group. GFR significantly improved in the ACCT group. EF, relative wall thickness, and LV mass did not differ between groups at 12 weeks. EDPVR improved in the ACCT group, indicating decreased ventricular stiffness. Intra-renal artery allogeneic cell therapy was safe in a CKD swine model manifesting the characteristics of HFpEF. The beneficial effect on renal function and ventricular compliance in the ACCT group supports further research of cell therapy for cardiorenal syndrome. This study describes the development of a novel large animal model of chronic kidney disease (CKD)-induced heart failure with preserved ejection fraction (HFpEF). Renal intra-arterial delivery of allogeneic MSCs and KSCs improved glomerular filtration rate (GFR). RNA-Seq data showed decreased podocyte apoptosis, reactive oxygen species, inflammatory pathways, and renin-angiotensin system activation. Allogeneic cell combination therapy (ACCT) restored diastolic function toward normal and decreased titin protein markers of stiffness. Cell therapy also prevented the increase in blood pressure over time.
- 19 February 2022
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 11 (1) , 59-72
Open AccessAllogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction
Left ventricular hypertrophy and heart failure with preserved ejection fraction (HFpEF) are primary manifestations of the cardiorenal syndrome in patients with chronic kidney disease (CKD). Therapies that improve morbidity and mortality in HFpEF are lacking. Cell-based therapies promote cardiac repair in ischemic and non-ischemic cardiomyopathies. We hypothesized that cell-based therapy ameliorates CKD-induced HFpEF. Yorkshire pigs (n = 26) underwent 5/6 embolization-mediated nephrectomy. CKD was confirmed by increased creatinine and decreased glomerular filtration rate (GFR). Mean arterial pressure (MAP) was not different between groups from baseline to 4 weeks. HFpEF was evident at 4 weeks by increased LV mass, relative wall thickening, end-diastolic pressure, and end-diastolic pressure-volume relationship, with no change in ejection fraction (EF). Four weeks post-embolization, allogeneic (allo) bone marrow-derived mesenchymal stem cells (MSC; 1 × 107 cells), allo-kidney-derived stem cells (KSC; 1 × 107 cells), allo-cell combination therapy (ACCT; MSC + KSC; 1:1 ratio; total = 1 × 107 cells), or placebo (Plasma-Lyte) was delivered via intra-renal artery. Eight weeks post-treatment, there was a significant increase in MAP in the placebo group (21.89 ± 6.05 mmHg) compared to the ACCT group. GFR significantly improved in the ACCT group. EF, relative wall thickness, and LV mass did not differ between groups at 12 weeks. EDPVR improved in the ACCT group, indicating decreased ventricular stiffness. Intra-renal artery allogeneic cell therapy was safe in a CKD swine model manifesting the characteristics of HFpEF. The beneficial effect on renal function and ventricular compliance in the ACCT group supports further research of cell therapy for cardiorenal syndrome. This study describes the development of a novel large animal model of chronic kidney disease (CKD)-induced heart failure with preserved ejection fraction (HFpEF). Renal intra-arterial delivery of allogeneic MSCs and KSCs improved glomerular filtration rate (GFR). RNA-Seq data showed decreased podocyte apoptosis, reactive oxygen species, inflammatory pathways, and renin-angiotensin system activation. Allogeneic cell combination therapy (ACCT) restored diastolic function toward normal and decreased titin protein markers of stiffness. Cell therapy also prevented the increase in blood pressure over time.
- Open Access
- 1 November 2020
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 116 (13) , 2131-2141
The impact of patient sex on the response to intramyocardial mesenchymal stem cell administration in patients with non-ischaemic dilated cardiomyopathy
Sex differences impact the occurrence, presentation, prognosis, and response to therapy in heart disease. Particularly, the phenotypic presentation of patients with non-ischaemic dilated cardiomyopathy (NIDCM) differs between men and women. However, whether the response to mesenchymal stem cell (MSC) therapy is influenced by sex remains unknown. We hypothesize that males and females with NIDCM respond similarly to MSC therapy. Male (n = 24) and female (n = 10) patients from the POSEIDON-DCM trial who received MSCs via transendocardial injections were evaluated over 12 months. Endothelial function was measured at baseline and 3 months post-transendocardial stem cell injection (TESI). At baseline, ejection fraction (EF) was lower (P = 0.004) and end-diastolic volume (EDV; P = 0.0002) and end-systolic volume (ESV; P = 0.0002) were higher in males vs. females. In contrast, baseline demographic characteristics, Minnesota Living with Heart Failure Questionnaire (MLHFQ), and 6-min walk test (6MWT) were similar between groups. EF improved in males by 6.2 units (P = 0.04) and in females by 8.6 units (P = 0.04; males vs. females, P = 0.57). EDV and ESV were unchanged over time. The MLHFQ score, New York Heart Association (NYHA) class, endothelial progenitor cell-colony forming units, and serum tumour necrosis factor alpha improved similarly in both groups. Despite major differences in phenotypic presentation of NIDCM in males and females, this study is the first of its kind to demonstrate that MSC therapy improves a variety of parameters in NIDCM irrespective of patient sex. These findings have important clinical and pathophysiologic implications regarding the impact of sex on responses to cell-based therapy for NIDCM.
- 1 November 2020
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 116 (13) , 2131-2141
Open AccessThe impact of patient sex on the response to intramyocardial mesenchymal stem cell administration in patients with non-ischaemic dilated cardiomyopathy
Sex differences impact the occurrence, presentation, prognosis, and response to therapy in heart disease. Particularly, the phenotypic presentation of patients with non-ischaemic dilated cardiomyopathy (NIDCM) differs between men and women. However, whether the response to mesenchymal stem cell (MSC) therapy is influenced by sex remains unknown. We hypothesize that males and females with NIDCM respond similarly to MSC therapy. Male (n = 24) and female (n = 10) patients from the POSEIDON-DCM trial who received MSCs via transendocardial injections were evaluated over 12 months. Endothelial function was measured at baseline and 3 months post-transendocardial stem cell injection (TESI). At baseline, ejection fraction (EF) was lower (P = 0.004) and end-diastolic volume (EDV; P = 0.0002) and end-systolic volume (ESV; P = 0.0002) were higher in males vs. females. In contrast, baseline demographic characteristics, Minnesota Living with Heart Failure Questionnaire (MLHFQ), and 6-min walk test (6MWT) were similar between groups. EF improved in males by 6.2 units (P = 0.04) and in females by 8.6 units (P = 0.04; males vs. females, P = 0.57). EDV and ESV were unchanged over time. The MLHFQ score, New York Heart Association (NYHA) class, endothelial progenitor cell-colony forming units, and serum tumour necrosis factor alpha improved similarly in both groups. Despite major differences in phenotypic presentation of NIDCM in males and females, this study is the first of its kind to demonstrate that MSC therapy improves a variety of parameters in NIDCM irrespective of patient sex. These findings have important clinical and pathophysiologic implications regarding the impact of sex on responses to cell-based therapy for NIDCM.